Additional Considerations Required While Assessing Jiangxi Sanxin MedtecLtd's (SZSE:300453) Strong Earnings
Additional Considerations Required While Assessing Jiangxi Sanxin MedtecLtd's (SZSE:300453) Strong Earnings
Jiangxi Sanxin Medtec Co.,Ltd. (SZSE:300453) announced strong profits, but the stock was stagnant. We did some digging, and we found some concerning factors in the details.
江西三鑫医疗股份有限公司(SZSE:300453)宣布盈利较好,但股票走势平稳。我们进行了一番调查,发现了一些细节中的令人担忧的因素。
The Impact Of Unusual Items On Profit
除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。
For anyone who wants to understand Jiangxi Sanxin MedtecLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥41m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).
对于想要了解江西三鑫医疗股份有限公司利润超出法定数字的人来说,重要的是要注意,在过去十二个月的法定利润中,有超过4100万元人民币的飞凡项目。虽然利润更高总是件好事,但飞凡项目的大幅贡献有时会消减我们的热情。当我们分析全球绝大多数上市公司时,发现重大飞凡项目往往不会重复出现。这一点并不奇怪,鉴其名称。假设这些飞凡项目在当前年度内不再出现,那么我们预计明年的利润将较弱(在没有业务增长的情况下)。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Jiangxi Sanxin MedtecLtd.
注:我们始终建议投资者检查资产负债表实力。单击这里查看我们对江西三鑫医疗股份有限公司财务状况分析。
Our Take On Jiangxi Sanxin MedtecLtd's Profit Performance
我们对江西三鑫医疗股份有限公司的盈利表现看法
Arguably, Jiangxi Sanxin MedtecLtd's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Jiangxi Sanxin MedtecLtd's true underlying earnings power is actually less than its statutory profit. But at least holders can take some solace from the 52% per annum growth in EPS for the last three. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. At Simply Wall St, we found 1 warning sign for Jiangxi Sanxin MedtecLtd and we think they deserve your attention.
可以说,三鑫医疗有限公司的法定收益受到了异常项目的影响,从而提高了利润。 因此,我们认为三鑫医疗有限公司真正的基础收益能力实际上可能低于其法定利润。 但至少持有人可以从过去三年每股收益增长52%中获得一些安慰。 当然,当涉及到分析其收益时,我们只是皮毛之下; 人们还可以考虑毛利率、预测增长和投资回报率等其他因素。 鉴于此,如果您想对该公司进行更多分析,了解相关风险是至关重要的。 在Simply Wall St,我们发现三鑫医疗有限公司有1个风险警告提示,我们认为这值得您关注。
This note has only looked at a single factor that sheds light on the nature of Jiangxi Sanxin MedtecLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
这篇笔记仅仅考虑了揭示三鑫医疗有限公司利润性质的单一因素。 但是,如果您有能力把注意力集中在细枝末节上,总是可以发现更多。 例如,许多人认为高净资产回报率是有利的商业经济的指标,而其他人则喜欢“跟着钱走”,寻找内部人员正在购买的股票。 尽管这可能需要一些研究,但您可能会发现这个收集高净资产回报率公司的免费清单,或者具有内部重要持股股票的清单对您有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。